# Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）

> **NCT02188082** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 336 (estimated)

## Conditions studied

- Chronic Systolic Heart Failure

## Interventions

- **DRUG:** IvabRadine hemisulfate Sustained-release Tablets
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02188082
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05
- **Primary completion:** 2017-08
- **Final completion:** —
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2014-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02188082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02188082, "Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02188082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*